Pacira Pharmaceuticals Given Average Rating of “Buy” by Brokerages (NASDAQ:PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) has been given a consensus rating of “Buy” by the ten analysts that are covering the stock, ARN reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $104.68.
A number of research firms have recently commented on PCRX. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00.
In other Pacira Pharmaceuticals news, Director Andreas Wicki sold 150,000 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $101.25, for a total value of $15,187,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 104.73 on Thursday. Pacira Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $106.42. The stock has a 50-day moving average of $93.2 and a 200-day moving average of $79.29. The company’s market cap is $3.759 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings data on Thursday, July 31st. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. The company’s revenue for the quarter was up 175.2% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $0.23 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.